RU2005113247A - Производные пиперазина и пиперидина для лечения неврологических заболеваний - Google Patents
Производные пиперазина и пиперидина для лечения неврологических заболеваний Download PDFInfo
- Publication number
- RU2005113247A RU2005113247A RU2005113247/04A RU2005113247A RU2005113247A RU 2005113247 A RU2005113247 A RU 2005113247A RU 2005113247/04 A RU2005113247/04 A RU 2005113247/04A RU 2005113247 A RU2005113247 A RU 2005113247A RU 2005113247 A RU2005113247 A RU 2005113247A
- Authority
- RU
- Russia
- Prior art keywords
- straight
- alkenyl
- branched chain
- disease
- branched
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 40
- 201000010099 disease Diseases 0.000 title claims 24
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 1
- 230000000926 neurological effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 21
- 238000000034 method Methods 0.000 claims abstract 14
- 230000006378 damage Effects 0.000 claims abstract 13
- 239000000203 mixture Substances 0.000 claims abstract 9
- 210000005036 nerve Anatomy 0.000 claims abstract 7
- 125000000217 alkyl group Chemical group 0.000 claims 23
- -1 pyraxolyl Chemical group 0.000 claims 23
- 125000000304 alkynyl group Chemical group 0.000 claims 22
- 208000035475 disorder Diseases 0.000 claims 16
- 229910052717 sulfur Inorganic materials 0.000 claims 16
- 229910052757 nitrogen Inorganic materials 0.000 claims 15
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 14
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 14
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 12
- 208000033808 peripheral neuropathy Diseases 0.000 claims 12
- 102000007072 Nerve Growth Factors Human genes 0.000 claims 10
- 125000003342 alkenyl group Chemical group 0.000 claims 10
- 210000002569 neuron Anatomy 0.000 claims 10
- 201000001119 neuropathy Diseases 0.000 claims 10
- 230000007823 neuropathy Effects 0.000 claims 10
- 239000003900 neurotrophic factor Substances 0.000 claims 10
- 229910052760 oxygen Inorganic materials 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- 208000024827 Alzheimer disease Diseases 0.000 claims 8
- 206010028289 Muscle atrophy Diseases 0.000 claims 8
- 102000006386 Myelin Proteins Human genes 0.000 claims 8
- 108010083674 Myelin Proteins Proteins 0.000 claims 8
- 208000012287 Prolapse Diseases 0.000 claims 8
- 230000020763 muscle atrophy Effects 0.000 claims 8
- 201000000585 muscular atrophy Diseases 0.000 claims 8
- 210000005012 myelin Anatomy 0.000 claims 8
- 230000001537 neural effect Effects 0.000 claims 8
- 230000000750 progressive effect Effects 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 7
- 210000004126 nerve fiber Anatomy 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims 4
- 241000238876 Acari Species 0.000 claims 4
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 claims 4
- 208000021401 Facial Nerve injury Diseases 0.000 claims 4
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims 4
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 4
- 208000021965 Glossopharyngeal Nerve disease Diseases 0.000 claims 4
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 4
- 206010019909 Hernia Diseases 0.000 claims 4
- 208000023105 Huntington disease Diseases 0.000 claims 4
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 4
- 208000029549 Muscle injury Diseases 0.000 claims 4
- 102000015336 Nerve Growth Factor Human genes 0.000 claims 4
- 208000028389 Nerve injury Diseases 0.000 claims 4
- 102000004230 Neurotrophin 3 Human genes 0.000 claims 4
- 108090000742 Neurotrophin 3 Proteins 0.000 claims 4
- 108090000099 Neurotrophin-4 Proteins 0.000 claims 4
- 102100033857 Neurotrophin-4 Human genes 0.000 claims 4
- 208000018737 Parkinson disease Diseases 0.000 claims 4
- 208000020339 Spinal injury Diseases 0.000 claims 4
- 206010041591 Spinal osteoarthritis Diseases 0.000 claims 4
- 208000000323 Tourette Syndrome Diseases 0.000 claims 4
- 208000016620 Tourette disease Diseases 0.000 claims 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 4
- 150000003857 carboxamides Chemical class 0.000 claims 4
- 206010061592 cardiac fibrillation Diseases 0.000 claims 4
- 208000036319 cervical spondylosis Diseases 0.000 claims 4
- 238000002512 chemotherapy Methods 0.000 claims 4
- 230000001886 ciliary effect Effects 0.000 claims 4
- 229960000860 dapsone Drugs 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000002600 fibrillogenic effect Effects 0.000 claims 4
- 201000005442 glossopharyngeal neuralgia Diseases 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 208000028867 ischemia Diseases 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- 208000005264 motor neuron disease Diseases 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 230000008764 nerve damage Effects 0.000 claims 4
- 229940053128 nerve growth factor Drugs 0.000 claims 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims 4
- 229940032018 neurotrophin 3 Drugs 0.000 claims 4
- 230000002093 peripheral effect Effects 0.000 claims 4
- 150000004032 porphyrins Chemical class 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 210000003497 sciatic nerve Anatomy 0.000 claims 4
- 208000020431 spinal cord injury Diseases 0.000 claims 4
- 208000005801 spondylosis Diseases 0.000 claims 4
- 229940124530 sulfonamide Drugs 0.000 claims 4
- 150000003456 sulfonamides Chemical class 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 4
- 208000023697 ABri amyloidosis Diseases 0.000 claims 3
- 208000006373 Bell palsy Diseases 0.000 claims 3
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 3
- 201000000162 ITM2B-related cerebral amyloid angiopathy 1 Diseases 0.000 claims 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 3
- 102000014429 Insulin-like growth factor Human genes 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 208000036826 VIIth nerve paralysis Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 125000004212 difluorophenyl group Chemical group 0.000 claims 3
- 125000001207 fluorophenyl group Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 210000003205 muscle Anatomy 0.000 claims 3
- 206010028417 myasthenia gravis Diseases 0.000 claims 3
- 208000027232 peripheral nervous system disease Diseases 0.000 claims 3
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims 2
- 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims 2
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 claims 2
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 claims 2
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 claims 2
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 claims 2
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 claims 2
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 claims 2
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 claims 2
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 claims 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims 2
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims 2
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims 2
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 claims 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims 2
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 claims 2
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 102000003683 Neurotrophin-4 Human genes 0.000 claims 2
- 230000002378 acidificating effect Effects 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 125000003828 azulenyl group Chemical group 0.000 claims 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 230000002490 cerebral effect Effects 0.000 claims 2
- 125000000068 chlorophenyl group Chemical group 0.000 claims 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims 2
- 239000002131 composite material Substances 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 108700001680 des-(1-3)- insulin-like growth factor 1 Proteins 0.000 claims 2
- 125000004188 dichlorophenyl group Chemical group 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 210000004498 neuroglial cell Anatomy 0.000 claims 2
- 229940097998 neurotrophin 4 Drugs 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 238000007911 parenteral administration Methods 0.000 claims 2
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims 2
- 125000002755 pyrazolinyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 2
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 2
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 claims 2
- 238000011084 recovery Methods 0.000 claims 2
- 125000006413 ring segment Chemical class 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 claims 1
- 210000003737 chromaffin cell Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 230000002518 glial effect Effects 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 230000036473 myasthenia Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 150000002829 nitrogen Chemical group 0.000 claims 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 210000000115 thoracic cavity Anatomy 0.000 claims 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 abstract 2
- 230000003961 neuronal insult Effects 0.000 abstract 2
- 230000004936 stimulating effect Effects 0.000 abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 150000003053 piperidines Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41613402P | 2002-10-03 | 2002-10-03 | |
| US60/416,134 | 2002-10-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2005113247A true RU2005113247A (ru) | 2006-01-20 |
Family
ID=32069937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005113247/04A RU2005113247A (ru) | 2002-10-03 | 2003-10-02 | Производные пиперазина и пиперидина для лечения неврологических заболеваний |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20040180880A1 (enExample) |
| EP (1) | EP1546103B1 (enExample) |
| JP (1) | JP2006504717A (enExample) |
| KR (1) | KR20050047132A (enExample) |
| CN (1) | CN100395236C (enExample) |
| AT (1) | ATE425967T1 (enExample) |
| AU (1) | AU2003299145A1 (enExample) |
| CA (1) | CA2500672A1 (enExample) |
| DE (1) | DE60326742D1 (enExample) |
| ES (1) | ES2324293T3 (enExample) |
| MX (1) | MXPA05003471A (enExample) |
| NO (1) | NO20052153L (enExample) |
| PL (1) | PL376149A1 (enExample) |
| RU (1) | RU2005113247A (enExample) |
| TW (1) | TW200533653A (enExample) |
| WO (1) | WO2004031148A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2486918C1 (ru) * | 2011-10-25 | 2013-07-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Способ стимулирования восстановления периферической иннервации тканей с помощью векторных конструкций |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7393656B2 (en) * | 2001-07-10 | 2008-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for risk stratification |
| GB0508319D0 (en) | 2005-04-25 | 2005-06-01 | Novartis Ag | Organic compounds |
| JP2009504637A (ja) * | 2005-08-08 | 2009-02-05 | アストラゼネカ・アクチエボラーグ | 治療薬 |
| US7943622B2 (en) | 2006-06-06 | 2011-05-17 | Cornerstone Therapeutics, Inc. | Piperazines, pharmaceutical compositions and methods of use thereof |
| EP2419413B1 (en) | 2009-04-16 | 2016-11-23 | Takeda Pharmaceutical Company Limited | Derivatives of n-acyl-n'-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes |
| HK1256751A1 (zh) | 2015-11-02 | 2019-10-04 | Janssen Pharmaceutica Nv | [1，2，4]三唑并[1，5-a]嘧啶-7-基化合物 |
| ES2912264T3 (es) | 2016-11-02 | 2022-05-25 | Janssen Pharmaceutica Nv | Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de PDE2 |
| EA039102B1 (ru) | 2016-11-02 | 2021-12-03 | Янссен Фармацевтика Нв | Соединения [1,2,4]триазоло[1,5-a]пиримидина в качестве ингибиторов pde2 |
| TWI764950B (zh) | 2016-11-02 | 2022-05-21 | 比利時商健生藥品公司 | Ｐｄｅ２抑制劑 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2597100A1 (fr) * | 1986-01-21 | 1987-10-16 | Nippon Shinyaku Co Ltd | Derives du pyroglutamide |
| US5889006A (en) * | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
| US5780484A (en) * | 1996-11-13 | 1998-07-14 | Vertex Pharmaceuticals Incorporated | Methods for stimulating neurite growth with piperidine compounds |
| US5811434A (en) * | 1996-11-13 | 1998-09-22 | Vertex Pharmacueticals Incorporated | Methods and compositions for stimulating neurite growth |
| US5721256A (en) | 1997-02-12 | 1998-02-24 | Gpi Nil Holdings, Inc. | Method of using neurotrophic sulfonamide compounds |
| WO1999010340A1 (en) * | 1997-08-29 | 1999-03-04 | Vertex Pharmaceuticals Incorporated | Compounds possessing neuronal activity |
| US6331537B1 (en) * | 1998-06-03 | 2001-12-18 | Gpi Nil Holdings, Inc. | Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds |
| US6264991B1 (en) * | 1998-08-18 | 2001-07-24 | Southern Research Institute | Compositions and methods for treating intracellular infections |
| KR20020073586A (ko) * | 2000-02-11 | 2002-09-27 | 버텍스 파마슈티칼스 인코포레이티드 | 피페라진 및 피페리딘 유도체 |
| US20040034019A1 (en) * | 2002-08-08 | 2004-02-19 | Ronald Tomlinson | Piperazine and piperidine derivatives |
-
2003
- 2003-10-02 PL PL03376149A patent/PL376149A1/xx not_active Application Discontinuation
- 2003-10-02 MX MXPA05003471A patent/MXPA05003471A/es not_active Application Discontinuation
- 2003-10-02 RU RU2005113247/04A patent/RU2005113247A/ru not_active Application Discontinuation
- 2003-10-02 ES ES03756899T patent/ES2324293T3/es not_active Expired - Lifetime
- 2003-10-02 KR KR1020057005779A patent/KR20050047132A/ko not_active Withdrawn
- 2003-10-02 AU AU2003299145A patent/AU2003299145A1/en not_active Abandoned
- 2003-10-02 EP EP03756899A patent/EP1546103B1/en not_active Expired - Lifetime
- 2003-10-02 DE DE60326742T patent/DE60326742D1/de not_active Expired - Lifetime
- 2003-10-02 CN CNB2003801041723A patent/CN100395236C/zh not_active Expired - Fee Related
- 2003-10-02 US US10/677,631 patent/US20040180880A1/en not_active Abandoned
- 2003-10-02 AT AT03756899T patent/ATE425967T1/de not_active IP Right Cessation
- 2003-10-02 WO PCT/US2003/031080 patent/WO2004031148A1/en not_active Ceased
- 2003-10-02 JP JP2004541991A patent/JP2006504717A/ja active Pending
- 2003-10-02 CA CA002500672A patent/CA2500672A1/en not_active Abandoned
-
2004
- 2004-04-05 TW TW093109385A patent/TW200533653A/zh unknown
-
2005
- 2005-05-02 NO NO20052153A patent/NO20052153L/no not_active Application Discontinuation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2486918C1 (ru) * | 2011-10-25 | 2013-07-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Способ стимулирования восстановления периферической иннервации тканей с помощью векторных конструкций |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100395236C (zh) | 2008-06-18 |
| US20040180880A1 (en) | 2004-09-16 |
| MXPA05003471A (es) | 2005-07-01 |
| NO20052153L (no) | 2005-05-31 |
| AU2003299145A1 (en) | 2004-04-23 |
| EP1546103B1 (en) | 2009-03-18 |
| EP1546103A1 (en) | 2005-06-29 |
| CA2500672A1 (en) | 2004-04-15 |
| WO2004031148A1 (en) | 2004-04-15 |
| PL376149A1 (en) | 2005-12-27 |
| ES2324293T3 (es) | 2009-08-04 |
| KR20050047132A (ko) | 2005-05-19 |
| JP2006504717A (ja) | 2006-02-09 |
| DE60326742D1 (de) | 2009-04-30 |
| CN1717390A (zh) | 2006-01-04 |
| ATE425967T1 (de) | 2009-04-15 |
| TW200533653A (en) | 2005-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU741186B2 (en) | Methods and compositions for stimulating neurite growth using compounds with affinity for FKBP12 in combination with neurotrophic factors | |
| ES2206753T3 (es) | Metodos y composicionespara estimular el crecimiento de neuritas. | |
| US6528533B2 (en) | Azo amino acids derivatives | |
| RU2005113247A (ru) | Производные пиперазина и пиперидина для лечения неврологических заболеваний | |
| JP2001514177A5 (enExample) | ||
| EP1666037A2 (en) | Compositions for stimulating neurite growth | |
| US6849630B2 (en) | Cyclized amino acid derivatives | |
| RU2004100701A (ru) | Ациклические производные пиперазина и пиперидина, которые являются полезными для лечения повреждения нейронов | |
| US6660748B2 (en) | Bicyclic derivatives | |
| US6552041B2 (en) | Cyclized amide derivatives | |
| JP2006504717A5 (enExample) | ||
| US20020123493A1 (en) | Cyclic amine derivatives | |
| EP1196400A1 (en) | Amino-alkyl derivatives | |
| US20040072821A1 (en) | N-substituted glycine derivatives | |
| US20050065339A1 (en) | Amino-alkyl derivatives | |
| ZA200205933B (en) | Piperazine and piperidine derivatives. | |
| EP1196385A1 (en) | Beta-amino acid derivatives for the treatment of neurological diseases | |
| HK1094309A (en) | Methods and compositions for stimulating neurite growth using compounds with affinity for fkbp12 in combination with neurotrophic factors | |
| MXPA00011843A (en) | Aza-heterocyclic compounds used to treat neurological disorders and hair loss | |
| HK1094420A (en) | Compositions for stimulating neurite growth |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20080607 |